The IPO Buzz: Cancer Biotech Bicara Therapeutics (BCAX Proposed) Upsizes IPO By 25 Percent to $250 Million
Bicara Therapeutics (BCAX Proposed), a clinical biotech focused on head and neck squamous cell cancer, increased the size of its IPO to $250 million – up from $200 million initially – in an S-1/A filing after the closing bell on Wednesday, Sept. 11, 2024. The new terms calls for Bicera Therapeutics to offer 14.71 million […]
September 11, 2024 Read More